Cargando…

Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis

BACKGROUND: Small cell lung cancer (SCLC) is a very aggressive and proliferative disease, with little progress being having made for its treatment in decades. Our goal was to evaluate the effect of immune checkpoint inhibitors (ICIs) and identify optimal first-line interventions for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niu, Zhicheng, Guo, Shenghu, Cao, Jing, Zhang, Yuehua, Guo, Xiaojin, Grossi, Francesco, Ichiki, Yoshinobu, Li, You, Wang, Zhiyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106042/ https://www.ncbi.nlm.nih.gov/pubmed/33987403 http://dx.doi.org/10.21037/atm-21-1423

Ejemplares similares

The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)

Immune profile analysis of peripheral blood and tumors of lung cancer patients treated with immune checkpoint inhibitors
por: Ichiki, Yoshinobu, et al.
Publicado: (2022)

Long non-coding RNA TUG1 enhances chemosensitivity in non-small cell lung cancer by impairing microRNA-221-dependent PTEN inhibition
por: Guo, Shenghu, et al.
Publicado: (2019)

Two Types of Immune Checkpoint Inhibitor-related Pancreatitis
por: Ichiki, Tomoko, et al.
Publicado: (2021)

Clinical Efficacy of Immune Checkpoint Inhibitors in Older Non-small-Cell Lung Cancer Patients: A Meta-Analysis
por: Sun, You-Meng, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
por: Tang, Shengjie, et al.
Publicado: (2022)

Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non‐small cell lung cancer
por: Kuo, Chih‐Hsi Scott, et al.
Publicado: (2019)

Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
por: Guaitoli, Giorgia, et al.
Publicado: (2021)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
por: Niu, Yuchun, et al.
Publicado: (2020)

Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors
por: Kurozumi, Atsumasa, et al.
Publicado: (2021)

Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges
por: Regzedmaa, Orgilmaa, et al.
Publicado: (2019)

Advances in immune checkpoint inhibitors therapy for small cell lung cancer
por: Li, Longhui, et al.
Publicado: (2023)

Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
por: Liu, Wei, et al.
Publicado: (2020)

Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status
por: Kano, Hirohisa, et al.
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis
por: Zhang, Rui, et al.
Publicado: (2021)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
por: Zhai, Xiaoyang, et al.
Publicado: (2020)

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
por: Ren, Sijia, et al.
Publicado: (2021)

Immune-Checkpoint Inhibitors as the First Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Chen, Yuqiao, et al.
Publicado: (2019)

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis
por: Yang, Fang, et al.
Publicado: (2022)

Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis
por: Li, Lin‐Lu, et al.
Publicado: (2023)

Smoking history and the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis
por: Chen, Da-Li, et al.
Publicado: (2021)

Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Jung, Chi Young, et al.
Publicado: (2018)

Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
por: Qiu, Zhenbin, et al.
Publicado: (2019)

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
por: Soh, Junichi, et al.
Publicado: (2021)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Ushio, Ryota, et al.
Publicado: (2022)

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
por: Altaf, Reem, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer
por: Schlick, Brian, et al.
Publicado: (2022)

Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer
por: He, Jiahui, et al.
Publicado: (2023)

Beyond Abscopal Effect: A Meta-Analysis of Immune Checkpoint Inhibitors and Radiotherapy in Advanced Non-Small Cell Lung Cancer
por: Fiorica, Francesco, et al.
Publicado: (2021)

Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?
por: Bauckneht, Matteo, et al.
Publicado: (2017)

Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies
por: Guo, Xinyu, et al.
Publicado: (2023)

Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer
por: Sugano, Teppei, et al.
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

CCL5 as a Prognostic Marker for Survival and an Indicator for Immune Checkpoint Therapies in Small Cell Lung Cancer
por: Tang, Yichun, et al.
Publicado: (2022)

Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?
por: Guo, Haoyue, et al.
Publicado: (2020)

Immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer: a systematic review and meta-analysis
por: Ge, Sa, et al.
Publicado: (2022)

Role of immune-checkpoint inhibitors in lung cancer
por: Jain, Prantesh, et al.
Publicado: (2018)

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
por: Wan, Rui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6phub9vh8mvv2o2e9l7b6el86h